Vinorelbine

Generic Name: Vinorelbine

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₄N_₄O_₈

CAS Number: 71486-22-1

Unique Ingredient Identifier: Q6C979R91Y

Background: Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .

It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .

Indication: Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .

For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .

For the treatment of recurrent or metastatic squamous cell head and neck cancer .

For the treatment of recurrent ovarian cancer .

For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .

For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .

Associated Conditions: Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma

Clinical Trials

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Phase 2

Recruiting

Conditions: Relapsed/Refractory Large B-Cell Lymphoma

Interventions: Drug: Linperlisib
Drug: Rituximab
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Dexamethasone
Drug: Cisplatin
Drug: Ara-C
Drug: Vinorelbine
Drug: Mitoxantrone hydrochloride liposome

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 89

Registration Number: NCT06489808

Locations: 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Biological: Sacituzumab Tirumotecan
Drug: Pemetrexed
Biological: Tisotumab Vedotin
Drug: Topotecan
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Irinotecan

First Posted Date: 2024-06-14

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 686

Registration Number: NCT06459180

Locations: 🇺🇸
USA Mitchell Cancer Institute-Clinical Trials ( Site 4126), Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center ( Site 4137), Anchorage, Alaska, United States
🇺🇸
HonorHealth (HH) ( Site 8002), Phoenix, Arizona, United States

and more 205 locations

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Phase 3

Recruiting

Conditions: Metastatic HER2-positive Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Zanidatamab
Drug: Eribulin
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Capecitabine

First Posted Date: 2024-05-30

Last Posted Date: 2025-05-21

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 550

Registration Number: NCT06435429

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Canada
🇺🇸
Arizona Oncology Tucson - Wilmot, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

and more 114 locations

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3

Recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: BL-B01D1
Drug: Eribulin
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Capecitabine

First Posted Date: 2024-04-24

Last Posted Date: 2025-05-02

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 436

Registration Number: NCT06382142

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab vedotin
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Vinorelbine
Diagnostic Test: FDG-PET/CT scan

First Posted Date: 2024-04-22

Last Posted Date: 2025-04-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 71

Registration Number: NCT06377566

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

and more 5 locations